

To: [REDACTED] [REDACTED]@rivm.nl; [REDACTED] [REDACTED]@rivm.nl
From: [REDACTED]
Sent: Thur 5/7/2020 8:26:07 AM
Subject: RE: CONFIDENTIAL; request to review Nature Communications manuscript NCOMMS-20-15154
Received: Thur 5/7/2020 8:26:08 AM

Ondanks dat ik het artikel niet kan zien / lezen zou ik zeggen afkeuren *

From: [REDACTED] <[REDACTED]@rivm.nl>
Sent: donderdag 7 mei 2020 10:07
To: [REDACTED] <[REDACTED]@rivm.nl>; [REDACTED] <[REDACTED]@rivm.nl>
Subject: FW: CONFIDENTIAL; request to review Nature Communications manuscript NCOMMS-20-15154

Ter info

From: [REDACTED]@nature.com <[REDACTED]@nature.com>
Sent: donderdag 7 mei 2020 10:05
To: [REDACTED] <[REDACTED]@rivm.nl>
Subject: CONFIDENTIAL; request to review Nature Communications manuscript NCOMMS-20-15154

Dear [REDACTED]

A manuscript has been submitted to Nature Communications, which we were hoping you would be interested in reviewing. The manuscript comes from [REDACTED] and colleagues and is entitled "Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray"; the abstract is appended below.

We would hope to receive your comments within 9 days to expedite the processing of COVID-19-related manuscripts to help resolve this public health crisis.

IMPORTANT

Nature Communications uses a transparent peer review system for new manuscripts submitted from January 2016. If the manuscript is accepted, the authors may agree for the reviewer comments to the authors as well as the author rebuttal letters to be published as a supplementary file associated with the paper. Any confidential comments between you and the editor will not be published. By submitting a reviewer report you agree to the publication of the comments made to the authors. Unless you sign the report with your name in those comments to the authors, we will respect and maintain your full anonymity. For more information, please refer to our FAQ page at <https://media.nature.com/full/nature-assets/ncomms/authors/ncomms-transparent-peer-review.pdf>

To respond to our request, please use the following link:

[REDACTED]
5.1.2h

From there, simply follow the link to manuscript NCOMMS-20-15154, where you will be able to view general manuscript information followed by options to accept or decline our request.

If you are unable to help on this occasion, we would appreciate any suggestions for alternative reviewers, keeping in mind that Nature journals strive toward a diverse demographic representation within our reviewer database, for example, with respect to gender and geography – perhaps someone in your own laboratory might be suitably qualified?

Please note that on a case by case basis we coordinate a brief consultation between referees and editors after all referee reports have been received. This is to improve the peer review process and the feedback provided to authors. If we decide to submit this paper to this process, you will be given the opportunity to make comments on your peers' concerns and potentially update your report to comment on the issues raised by the other reviewers before we send a final decision. We may therefore contact you after we receive your review to ask you for further feedback. If you would prefer not to participate in this process, please let me know.

Many thanks in advance for your help; I look forward to hearing from you. Please don't hesitate to contact me by replying to this e-mail if you have any questions.

Best regards,

5.1.2e

Nature Communications

5.1.2e

5.1.2e

The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from use of antigen combinations that include both spike protein and nucleoprotein. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.

Please note that your contact details are being held on our editorial databases which are used only for the management of the peer review process, and we might contact you in relation to Nature Research journals other than this one when your expertise is appropriate. If you would prefer us not to contact you in the future please let us know by emailing

5.1.2e

[@nature.com](mailto:5.1.2e@nature.com).

COVID 19 and impact on peer review

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

This email has been sent through the Springer Nature Tracking System NY-610A-NPG&MTS

Confidentiality Statement:

This e-mail is confidential and subject to copyright. Any unauthorised use or disclosure of its contents is prohibited. If you have received this email in error please notify our Manuscript Tracking System Helpdesk team at <http://platformsupport.nature.com>.

Details of the confidentiality and pre-publicity policy may be found here

<http://www.nature.com/authors/policies/confidentiality.html>

[Privacy Policy](#) | [Update Profile](#)

DISCLAIMER: This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage mechanism. Springer Nature Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of Springer Nature Ltd or one of their agents.

Please note that Springer Nature Limited and their agents and affiliates do not accept any responsibility for viruses or malware that may be contained in this e-mail or its attachments and it is your responsibility to scan the e-mail and attachments (if any).

Springer Nature Ltd. Registered office: The Campus, 4 Crinan Street, London, N1 9XW. Registered Number: 00785998 England.